Sarclisa
FDA Approves Sarclisa With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma
The FDA has approved isatuximab-irfc (Sarclisa, Sanofi-Aventis) with bortezomib, lenalidomide and dexamethasone for ...
SEPTEMBER 23, 2024
Compared With Standard Multiple Myeloma Therapy, Isatuximab Doubles Odds of MRD Negativity
In transplant-eligible patients with newly diagnosed multiple myeloma (MM), the novel anti-CD38 monoclonal antibody ...
FEBRUARY 23, 2024
FDA Approves Sarclisa Combination for Relapsed or Refractory Multiple Myeloma
The FDA approved isatuximab-irfc (Sarclisa, Sanofi Genzyme) in combination with carfilzomib and dexamethasone for ...
APRIL 6, 2021
New Monoclonal Antibody Approved to Treat Relapsed/Refractory MM
The FDA approved isatuximab-irfc (Sarclisa, Sanofi) in combination with pomalidomide (Pomalyst, Celgene) and ...
MARCH 3, 2020
Load more